Jump to any asset
849 assets, updated daily
As of September 15, 2026, Medtronic (MDT) trades at $93.75. CleaRank Financial AI rates it Buy with a fair value of $106.00, 13.1% above the current price. Wall Street's consensus target is $106.00 across 29 analysts. RSI at 57 is in neutral territory, and the price is above its 50-day average of $88.10.
Medtronic (MDT)
Medtronic NYSE
$93.75
-0.0500 (-0.05%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
70 / 100
Medtronic (MDT) is trading at $93.75, above its 50-day and 200-day moving averages ($88.10 and $89.44), indicating a positive near-term trend. The company has demonstrated consistent earnings beats, with the latest quarter to September 2026 exceeding estimates by 4.32%. Revenue growth is projected to be around 6.00% for the current and next quarters, and 7.00% for the current year, aligning with sector averages. The stock's fair value is estimated at $106.00, offering a potential upside of 13.1% based on the median analyst target price. Medtronic operates within the Healthcare sector, specifically in Medical Devices, a segment that shows a median P/E of 31.9 and revenue growth of 8.1%. The company's own profit margin stands at 13.93%, with a debt-to-equity ratio of 0.55, which is in line with sector averages. Despite a moderate sell signal from insider transactions, with total sales of $9.6M versus purchases of $462.8K, the overall analyst sentiment remains predominantly positive, with 20 out of 29 analysts rating the stock as a Buy or Strong Buy.
MDT Price Analysis
Market Metrics
Open
$93.69
Day Range
$92.73 to $94.70
Prev Close
$93.80
Volume
7.15M
52-Week Range
$73.31 to $106.33
Market Cap
$119.92B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-30%), which may indicate undervaluation or specific company headwinds.
MDT Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, MDT beat estimates 4 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
MDT Analysis
Company's Health
4/5
12-Month Analyst Target
+13.07% Upside
Median of 29 analysts (12-month)
$106.00
AI Technical Analysis
Medtronic (MDT) is currently trading above its 50-day and 200-day moving averages ($88.10 and $89.44), signaling an upward trend. The Relative Strength Index (RSI) is at 57.12, indicating neutral momentum, while the MACD at 1.23 suggests a positive, albeit moderate, trend. The stock's price action over the last quarter has been constructive, consistently trading above key moving averages. Key support levels are near the 50-day SMA around $88.10, while resistance is observed near its recent highs. Volume has been slightly below average recently, with 7.15 million shares traded compared to an average of 8.73 million, suggesting a lack of strong conviction from traders at current levels.
ProTips
- Medtronic's (MDT) insider transactions show a moderate sell signal, with total sales significantly outweighing purchases. Investors should monitor future insider activity for any changes in sentiment.
- The stock is trading above its 50-day and 200-day moving averages ($88.10 and $89.44), indicating a bullish technical setup. However, recent volume has been below average, suggesting a lack of strong conviction.
- Consider position sizing carefully given the moderate insider sell signal, even though the overall analyst consensus remains positive.
Key Catalysts
Bullish
Positive Analyst Sentiment and Price Targets
A strong analyst consensus, with 20 out of 29 analysts rating MDT as Buy or Strong Buy, and a median price target of $106.00, suggests confidence in the company's future performance and offers a potential 13.1% upside.
Source: Wall Street AnalystsBullish
Consistent Earnings Performance
Medtronic (MDT) has a track record of meeting or exceeding earnings expectations, with the latest quarter to September 2026 showing a 4.32% EPS surprise, indicating operational strength.
Source: Earnings ReportsBullish
Attractive Valuation Relative to Sector
Medtronic's P/E ratio of 22.40 and P/S ratio of 3.10 are below sector medians, presenting a value opportunity within the Healthcare sector.
Source: Company FundamentalsBearish
Moderate Insider Selling Signal
Insider transactions indicate net selling pressure, with total sales of $9.6 million compared to purchases of $462.8K, which could signal a cautious outlook from management.
Source: Insider TransactionsBearish
Moderating Revenue Growth Projections
Projected revenue growth for next year is expected to slow to 4.00%, down from approximately 7.00% for the current year, which could impact future valuation multiples.
Source: Revenue EstimatesMarket Outlook
Medtronic (MDT) is expected to maintain its positive trajectory over the next 6-12 months, driven by its consistent earnings performance and attractive valuation. The median analyst target price of $106.00 suggests a potential upside of 13.1% from the current price of $93.75. The company's revenue is projected to grow by approximately 7.00% for the current year, slightly above the sector average. The positive analyst consensus, with a majority of ratings at Buy or Strong Buy, further supports this outlook. Potential upside catalysts include continued innovation in its medical device segments and favorable healthcare policy developments. Conversely, a significant shift in insider selling sentiment or a slowdown in projected revenue growth could present downside risks.
Key Statistics
| Market Cap | 119.92B |
|---|---|
| P/E Ratio | 22.40 |
| EPS (TTM) | 4.06 |
| Dividend Yield | 3.04% |
| 52 Week High | 106.33 |
| 52 Week Low | 73.31 |
Medtronic (MDT) exhibits a P/E ratio of 22.40, which is below the sector median of 31.9, suggesting a potentially attractive valuation. Its price-to-sales ratio of 3.10 is also below the sector median of 3.7. The company's return on equity stands at 10.65%, and its profit margin is 13.93%, both figures indicating solid profitability. With a debt-to-equity ratio of 0.55, Medtronic maintains a manageable leverage profile. The current valuation appears reasonable given the company's consistent earnings performance and projected revenue growth of approximately 7.00% for the current year, which slightly outpaces the sector average of 8.1%.
Earnings & Growth Analysis
Medtronic (MDT) has a history of meeting or exceeding earnings expectations, with the quarter to September 2026 showing an EPS surprise of 4.32%. The company has also demonstrated positive price reactions following earnings reports, such as a 0.46% increase after the quarter to June 2026. Revenue growth is projected to be around 6.00% for the current and next quarters, indicating sustained top-line expansion. This consistent performance suggests operational efficiency and effective market positioning.
Key Risks
A primary risk for Medtronic (MDT) stems from insider transactions, which show a moderate sell signal with total sales of $9.6 million compared to purchases of $462.8K. While the company's valuation is attractive relative to its sector, a significant portion of the selling activity is attributed to officers, which could signal a lack of confidence in near-term price appreciation. Also, while revenue growth is steady, the projected growth rate for next year is expected to moderate to 4.00%, which could impact future valuation multiples.
Technical Indicators
| RSI (14) | 57.12 |
|---|---|
| MACD | 1.23 |
| SMA 50 | 88.10 |
| SMA 200 | 89.44 |
RSI
Neutral
SMA Cross
Bearish
Price vs SMA
Bullish
MACD
Bullish
Moving averages show a lagging Death Cross (50-day: $88.10, 200-day: $89.44), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.25
Weak correlation
Nasdaq 100 (QQQ)
+0.11
Weak correlation
Bitcoin (BTC)
-0.18
Weak correlation
Gold (XAU)
+0.06
Weak correlation
Check Custom Correlation
How does any other asset move with MDT? One year of daily closes, Pearson correlation.
Try
MDT Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$91.88
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$93.75
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$88.94
MAX LOSS
-3.2%
Volatility-Adjusted Stop Loss
Calculated based on RSI (57.1) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$96.47
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$101.06
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$105.66
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for MDT is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 15, 2026.Growth of $10,000
A $10,000 investment in MDT in September 2016 would be worth about $10,950 today, compared with about $35,344 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MDT today could grow to about $14,389 by 2036 in the base case, with a bull case near $37,496 and a bear case around $5,522. Projections are statistical simulations, not guarantees.
MDT Stock Price Prediction: 2030
CleaRank's simulation projects a price near $108 for MDT by 2030 in the base case, from $93.75 today (1.2x over 4 years). The downside path ends near $59.17. These are outcomes of a Monte Carlo simulation run on MDT's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $71.82 | $97.22 | $132 |
| 2028 | $65.70 | $101 | $155 |
| 2029 | $61.88 | $105 | $177 |
| 2030 | $59.17 | $108 | $199 |
| 2031 | $57.13 | $112 | $221 |
| 2032 | $55.54 | $117 | $245 |
| 2033 | $54.27 | $121 | $270 |
| 2034 | $53.25 | $125 | $295 |
| 2035 | $52.43 | $130 | $323 |
| 2036 | $51.76 | $135 | $352 |
Method: 10,000 simulated price paths using MDT's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
MDT Insider Trading Analysis
Bought
$462.8K
1 Transactions
Sold
$9.6M
5 Transactions
Insiders
22
Active Traders
Avg Transaction
$1.7M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2019 | HAKAMI HOOMAN C.
Officer
|
Sell | 82.9K | $8.9M |
| Aug 31, 2021 | LERMAN BRADLEY E
General Counsel
|
Sell | 50.8K | $6.8M |
| Sep 30, 2021 | LERMAN BRADLEY E
General Counsel
|
Sell | 49.1K | $6.2M |
| Dec 24, 2019 | KUNTZ RICHARD E
Officer
|
Sell | 50.9K | $5.8M |
| Dec 2, 2019 | WHITE ROBERT JOHN
Officer
|
Sell | 52.2K | $5.8M |
| Nov 1, 2019 | WHITE ROBERT JOHN
Officer
|
Sell | 52.2K | $5.7M |
| Jun 12, 2019 | HAKAMI HOOMAN C.
Officer
|
Sell | 52.7K | $5.1M |
| Feb 19, 2026 | KIIL HARRY SKIP
Officer
|
Sell | 52.5K | $5.1M |
| Sep 24, 2018 | MARTHA GEOFFREY S
Officer
|
Sell | 49.8K | $4.9M |
| Aug 28, 2018 | KUNTZ RICHARD E
Officer
|
Sell | 47.2K | $4.5M |
Page 1 of 1
Frequently Asked Questions
Is Medtronic (MDT) stock a buy right now?
Medtronic (MDT) is currently rated as a Buy, with a consensus score of 70 and a median analyst target price of $106.00, suggesting a 13.1% upside from its current price of $93.75. The stock is trading above key moving averages and has a history of meeting earnings expectations.
What is Medtronic's (MDT) stock price forecast for 2030?
Based on Monte Carlo simulations, Medtronic's (MDT) stock price is projected to be $108.44 in 2030 under a base case scenario, with a downside projection of $59.17 and an upside projection of $198.73. These are statistical outcomes, not guarantees.
What are the key technical levels for Medtronic (MDT)?
Medtronic (MDT) is trading above its 50-day SMA of $88.10 and its 200-day SMA of $89.44, indicating a positive trend. The RSI is neutral at 57.12, suggesting no immediate overbought or oversold conditions.
How does Medtronic's (MDT) valuation compare to its peers?
Medtronic (MDT) trades at a P/E ratio of 22.40 and a price-to-sales ratio of 3.10, both of which are below the sector medians of 31.9 and 3.7, respectively, suggesting a potentially attractive valuation relative to the Healthcare sector.
What is the recent earnings performance of Medtronic (MDT)?
Medtronic (MDT) recently reported an EPS of $1.45 for the quarter to September 2026, exceeding estimates by 4.32%. The company has a consistent track record of meeting or beating earnings expectations.
Are there any significant insider transactions for Medtronic (MDT)?
Insider activity for Medtronic (MDT) indicates a moderate sell signal, with total sales of $9.6 million and purchases of $462.8K in recent filings. This suggests a net selling pressure from insiders.
What is the outlook for Medtronic (MDT) over the next 12 months?
The outlook for Medtronic (MDT) is positive, with a median analyst target price of $106.00, implying a 13.1% upside. The company is expected to continue its steady revenue growth and maintain its profitability, supported by a strong analyst consensus.